15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 14 firms covering Palvella Therapeutics, Inc, 14 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $133.00 to $270.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $198.85 sits 31% above the current $152.07. The rating mix has stayed broadly stable, with Buy-side ratings easing from 15 to 13 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-2.09 next quarter toward $-7.50 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 ratings
Strong Buy
Strong Buy17%
Buy1393%
Hold00%
Sell00%
Strong Sell00%
Based on 14 analysts giving stock ratings to Palvella Therapeutics, Inc.
As of Sep, 13 of 13 firms rate PVLA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PVLA EPS & revenue forecast
EPS · NEXT QUARTER
$-2.09
Range $-2.73 – $-1.21 · 12 analysts · +93% YoY
Next period, 12 analysts expect Palvella Therapeutics, Inc to earn $-2.09 a share (range $-2.73 – $-1.21), versus $-1.08 a year earlier. Full-year consensus is $-6.37, growing to $-7.50 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 12 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $28.9M next year.
Top analysts covering Palvella Therapeutics, Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PVLA.
#1
Andrew Fein
HC Wainwright & Co. · Rank #55
Buy
$270.00+77.5% to target
Overall win rate
46%
+ Follow
#2
Geulah Livshits
Chardan Capital · Rank #85
Buy
$240.00+57.8% to target
Overall win rate
46%
+ Follow
#3
Josh Schimmer
Cantor Fitzgerald · Rank #162
Buy
$200.00+31.5% to target
Overall win rate
38%
+ Follow
#4
WI
Whitney Ijem
Canaccord Genuity · Rank #350
Buy
$227.00+49.3% to target
Overall win rate
32%
+ Follow
#5
JM
Jeet Mukherjee
BTIG
Buy
$215.00+41.4% to target
Coverage
—
+ Follow
PVLA stock forecast FAQ
What is PVLA's average 12-month price target?+
The 13 analysts with a live target average $198.85 for Palvella Therapeutics, Inc over the next 12 months, ranging from a $270.00 high to a $133.00 low.
Is PVLA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 14 analyst ratings, 14 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PVLA?+
The Street-high target is $270.00 (HC Wainwright & Co.), and the Street-low is $133.00 (TD Cowen). The average of all 13 active targets is $198.85.
How many Wall Street analysts cover PVLA?+
14 analysts have an active rating on Palvella Therapeutics, Inc, and 13 firms carry a live 12-month price target.
Who is the most accurate analyst covering PVLA?+
Among analysts who currently cover PVLA, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #55). Their current call is Buy with a $270.00 target.
What is Palvella Therapeutics, Inc's projected EPS for next quarter?+
The consensus estimate is $-2.09 per share (range $-2.73 – $-1.21) across 12 analysts. Full-year EPS is projected at $-6.37, rising to $-7.50 the following year.
How much revenue is Palvella Therapeutics, Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $28.9M next year.
Have analysts been upgrading or downgrading PVLA lately?+
As of Sep, 13 of 13 firms rate PVLA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PVLA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
